Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, specifically targeting Gram-positive bacteria. The company's approach involves developing antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that inhibit the DNA polymerase IIIC (pol IIIC) enzyme, which is crucial for DNA replication in these bacteria, leading to bacterial cell death. The bacterial targets, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP), and B. anthracis (anthrax), are identified as priority pathogens by the World Health Organization (WHO), the U.S. Centers for Disease Control and Prevention (CDC), and the U.S. Food and Drug Administration (FDA) due to the global crisis of antimicrobial resistance (AMR). The CDC estimates that in the U.S., antibiotic-resistant pathogens infect one individual every 11 seconds and result in one death every 15 minutes, while bacterial AMR was directly responsible for 1.27 million global deaths in 2019 and contributed to 4.95 million deaths ¹.

The company's core business model is centered on the research and development of novel antibiotic candidates. Acurx Pharmaceuticals aims to "de-risk" this new class of antibiotics through its drug development activities and potentially partner with a fully-integrated pharmaceutical company for late-stage clinical trials and commercialization, or conduct Phase 3 clinical trials prior to such a partnership. The company has not generated any revenue since its inception and does not expect to generate revenue from product sales in the near future ². Revenue generation is entirely dependent on the successful development, regulatory approval, and commercialization of its product candidates, or through strategic partnerships, licensing, or other arrangements.

Acurx Pharmaceuticals' pipeline includes ibezapolstat (formerly ACX-362E) as its lead antibiotic candidate, which is a novel DNA pol IIIC inhibitor. This candidate has completed Phase 2 clinical trials for the oral treatment of C. difficile infection (CDI). The company also has an early-stage pipeline, including ACX-375C, a potential oral and parenteral treatment targeting Gram-positive bacteria such as MRSA, VRE, and PRSP, and B. anthracis (anthrax). The company believes ibezapolstat is the first antibiotic candidate to work by blocking the DNA pol IIIC enzyme in C. difficile ³.

Ibezapolstat has demonstrated clinical efficacy and a favorable safety profile. In the combined Phase 2 trials for CDI, the overall observed Clinical Cure rate was 96% (25 out of 26 patients) ⁴, with 100% (10 out of 10 patients) in Phase 2a and 94% (15 out of 16 patients) in Phase 2b ⁵. All 25 ibezapolstat-treated patients who achieved Clinical Cure at End of Treatment (EOT) remained free of CDI recurrence through one month after EOT, resulting in a Sustained Clinical Cure (SCC) rate of 100% ⁶. In contrast, the vancomycin control arm in Phase 2b showed a Clinical Cure rate of 100% (14 out of 14 patients) ⁷, but only 86% (12 of 14) for the vancomycin patient group remained cured through one month after EOT ⁸. Ibezapolstat was well-tolerated, with three patients in Phase 2b experiencing one mild, drug-related gastrointestinal adverse event each, which resolved without treatment ⁹. No drug-related treatment withdrawals or serious adverse events were reported in either segment of the Phase 2 clinical trial ¹⁰.

The company's second antibiotic candidate, ACX-375C, is in pre-clinical development and is expected to be eligible for FDA's QIDP and fast track designations ¹¹. This compound has demonstrated potent activity against clinically important pathogens including MRSA, VRE, and PRSP, with minimum inhibitory concentration (MIC) values of 1–4 µg/mL ¹². Recent microbiological testing also showed in vitro activity with MICs of 0.5-2mcg/mL against B. anthracis, including ciprofloxacin-resistant strains ¹³. The company has synthesized and tested over 600 novel analogs targeting pol IIIC, identifying 20 novel compounds with MIC values ≤1 µg/mL for both MRSA and VRE ¹⁴.

For the fiscal year ended December 31, 2025, Acurx Pharmaceuticals reported a net loss of $7.966 million ¹⁵, an improvement from a net loss of $14.103 million for the year ended December 31, 2024 ¹⁶. Total operating expenses decreased by 43% ¹⁷ to $8.092 million in 2025 from $14.123 million in 2024 ¹⁸. Research and development expenses were $1.835 million in 2025, down from $5.404 million in 2024, a decrease of $3.6 million ¹⁹. General and administrative expenses decreased by $2.4 million to $6.257 million in 2025 from $8.719 million in 2024 ²⁰. The company had cash of approximately $7.6 million as of December 31, 2025 ²¹, and working capital of $5.3 million ²². Basic and diluted net loss per common share was $(5.32) in 2025, compared to $(17.45) in 2024 ²³.

During 2025, the company undertook several significant operational and financing activities. On August 4, 2025, a 1-for-20 reverse stock split was effected, leading to compliance with Nasdaq's minimum bid price and stockholders' equity requirements ²⁴. The total number of authorized shares of common stock was increased from 200,000,000 to 250,000,000 on September 22, 2025 ²⁵. The company raised net proceeds of approximately $3.8 million through an Equity Line of Credit (ELOC) with Lincoln Park Capital Fund, LLC, as of December 31, 2025 ²⁶. Additionally, a warrant inducement agreement on June 17, 2025, generated net proceeds of approximately $2.5 million from the exercise of existing warrants ²⁷. Registered direct offerings in January and March 2025 yielded net proceeds of $2.1 million and $0.9 million, respectively ²⁸. The ATM program, under which $8.8 million in net proceeds were raised, was suspended as of January 6, 2025 ²⁹.

Acurx Pharmaceuticals anticipates a substantial increase in research and development expenses in the foreseeable future as it continues the development of its product candidates and seeks to discover and develop new ones. The company expects to incur significant commercialization expenses related to product manufacturing, marketing, sales, and distribution if any product candidates obtain regulatory approval. The costs for manufacturing any approved product candidate are expected to be substantial. The company believes its existing capital resources will not be sufficient to fund anticipated operations for at least 12 months from the issuance of its financial statements for the year ended December 31, 2025 ³⁰.

The company plans to advance ibezapolstat into international Phase 3 clinical trials for the treatment of C. difficile infection (CDI) ³¹. Following a successful End-of-Phase 2 meeting with the FDA in April 2024, formal regulatory guidance was received, allowing the company to finalize the size and scope of the Phase 3 clinical trial program and agree on NDA filing requirements in the U.S. ³². Regulatory guidance from the European Medicines Agency (EMA) in December 2024 also confirmed the acceptability of the Phase 3 clinical trial protocol and the pathway for marketing approval in the European Union if the trial is successful ³³. The company intends to include international clinical trial sites to enhance enrollment and provide data for approvals outside the U.S. in major pharmaceutical markets ³⁴.

Ibezapolstat has received FDA fast track designation and Qualified Infectious Disease Product (QIDP) status, which provides incentives under the GAIN Act, including FDA priority review and an extension of statutory exclusivity periods in the U.S. for an additional five years upon FDA marketing approval ³⁵. This results in a total of 10 years of regulatory exclusivity for the oral use of ibezapolstat to treat CDI from the date of FDA marketing approval ³⁶. The company also obtained small and medium-sized enterprises (SME) designation from the EMA in February 2024, which provides reduced fees and close interaction with regulatory authorities throughout the drug development process ³⁷.

Acurx Pharmaceuticals estimates that if ibezapolstat is approved with clinical data consistent with current data, it could capture over 40% of the CDI market in peak year sales ³⁸. At a preliminary price estimate of $3,000 to $3,500 per full course of treatment, this projects to estimated peak year sales of over $1 billion per year in the U.S. alone ³⁹. This market penetration assumes at least two other treatment options will be available in addition to ibezapolstat, despite only two antibiotics currently being recommended for CDI treatment, and oral vancomycin having vulnerabilities with a 20%-40% reinfection rate and poor impact on the microbiome ⁴⁰.

The company's early-stage pipeline includes ACX-375C, which is expected to be eligible for FDA QIDP and fast track designations ⁴¹. This is supported by its microbiological activity against qualifying pathogens like MRSA and VRE, which cause serious or life-threatening infections ⁴². The initial clinical indication for ACX-375C is targeting Gram-positive acute bacterial skin and skin structure infections (ABSSSI), with subsequent trials potentially targeting hospital-acquired bacterial pneumonia (HABP), bloodstream infections/endocarditis, diabetic foot infections, and osteomyelitis ⁴³. The company estimates a peak year sales potential of approximately $1 billion for ACX-375C, representing 4% to 5% of the annual incidence of approximately six million patients per year in the U.S. alone for these bacterial targets ⁴⁴. Patents for ACX-375C extend to FYE 2039 and it is eligible for FDA QIDP/Fast Track Designations, providing 10 years of regulatory exclusivity in the U.S. and other regulatory exclusivity periods ex-U.S. ⁴⁵.

Manufacturing of ibezapolstat drug substance (DS) has been successful in 1 kg and 9 kg batches, with 9 kg batches considered commercial scale. The company anticipates a commercial batch size of 10 kg to 15 kg upon NDA submission, which is expected to further reduce cost of goods ⁴⁶. The manufacturing process is believed to be efficient, with cost of goods sold expected to be less than 5% of proposed sales price estimates ⁴⁷. Ibezapolstat DS is stable for at least four years, allowing for strategic stockpiling ⁴⁸. Commercial supply of Regulatory Starting Materials (RSMs), DS, and Drug Product (DP) will be made in the United States ⁴⁹.

Planned capital allocation includes continued financing through public and private equity offerings, debt financings, strategic partnerships, and licensing arrangements until substantial product revenues are generated ⁵⁰. The company's 2021 Equity Incentive Plan allows for an automatic annual increase in reserved shares, equal to the lesser of 4% of outstanding common stock or a number determined by the plan administrator, for ten years starting January 2, 2022, and ending January 2, 2031 ⁵¹.

The company faces significant risks, including its status as a clinical-stage company with a limited operating history and recurring net losses, totaling approximately $75.2 million as of December 31, 2025 ⁵², which raise substantial doubt about its ability to continue as a going concern. There is a need for substantial additional funding, and the inability to raise capital on acceptable terms could force delays or elimination of product development and commercialization efforts. The success of the lead product candidate, ibezapolstat, is uncertain and dependent on successful completion of clinical development, regulatory approvals, establishment of commercial manufacturing, intellectual property protection, and market acceptance. Serious adverse side effects identified during development could lead to abandonment or limitation of product candidates. The biopharmaceutical industry is characterized by intense competition from larger, better-capitalized companies, and competitors may develop superior or less expensive products. Global, market, and economic conditions, including inflation, higher interest rates, potential recession, geopolitical tensions (such as the conflict between Russia and Ukraine, tensions involving China, and the conflict between the U.S., Israel, and Iran), and banking sector instability, could negatively impact the business and ability to raise capital ⁵³. Climate change and related legal/regulatory measures also pose physical and transitional risks to operations and supply chains. Failure to obtain adequate reimbursement from third-party payers or new restrictive legislation could limit market acceptance and revenue. The company relies on third-party manufacturers and CROs, which introduces risks related to supply, quality, regulatory compliance, and timely execution of clinical trials. Intellectual property litigation is a risk, potentially leading to substantial costs, diversion of resources, and invalidation of patents. Cybersecurity threats, including unauthorized access and data corruption, could result in information theft, operational disruption, and financial loss, with the company acknowledging it may not be sufficiently protected against such occurrences ⁵⁴. Evolving privacy and data protection laws, such as GDPR and CCPA, impose complex and costly compliance obligations, with potential for significant penalties for non-compliance.

Management's overall tone emphasizes the company's pioneering efforts in developing a new class of antibiotics targeting the DNA pol IIIC enzyme, which has been clinically validated as a therapeutically relevant antibacterial target. They highlight the successful completion of Phase 2 clinical trials for ibezapolstat in CDI, demonstrating a pooled Clinical Cure rate of 96% ⁵⁵ and a Sustained Clinical Cure rate of 100% ⁵⁶ for ibezapolstat-treated patients who achieved Clinical Cure at EOT, with a favorable safety profile. Management believes these results support demonstrating non-inferiority to vancomycin in Phase 3 trials, in accordance with FDA Guidance for Industry (October 2022) ⁵⁷, with favorable differentiation in both Clinical Cure and Sustained Clinical Cure. Key strategic priorities include advancing ibezapolstat into international Phase 3 clinical trials, leveraging FDA QIDP and Fast Track designations for accelerated development and extended market exclusivity (10 years in the U.S. ⁵⁸), and exploring strategic partnerships for late-stage clinical trials and commercialization. They also emphasize the development of the early-stage pipeline, ACX-375C, for systemic Gram-positive infections, anticipating similar regulatory designations and a significant market opportunity, with estimated peak year sales of over $1 billion per year in the U.S. alone for ibezapolstat ⁵⁹ and approximately $1 billion for ACX-375C ⁶⁰.